Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.
Allendale, NJ, USA and Taipei, Taiwan – October 2, 2024 Minaris Regenerative Medicine, LLC (Minaris) and TFBS Bioscience Inc. (TFBS) are pleased to announce a strategic partnership in cell and gene therapy (CGT) mainly in North America. This collaboration is designed to enhance their capabilities to drive industry innovation by providing the one-stop-shop solutions. The strategic partnership ...
Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. September 24, 2024. 2024年9月24日 Minaris Regeneraive Medicine株式会社 代表取締役社長 坂東 博人 Minarisグループに関する株式譲渡契約締結について 本日2024年9月24日付にて株式会社レゾナック・ホールディングスの連結子会社である株式会社レゾナックは、Minaris Regenerative Medicine株式会社、Minaris Regenerative Medicine, LLC（アメリカ）、及びMinaris Regenerative Medicine GmbH（ドイツ）（以下、3社を総称してMinarisグループ、取締役兼CEO坂東 ...
Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. September 24, 2024. Minaris Regenerative Medicine (“Minaris”), a leading cell therapy contract development and manufacturing organization, is pleased to announce that its parent company, Resonac Corporation (“Resonac”), has entered into a definitive agreement to sell Minaris to a fund managed by Altaris, LLC (collectively with its ...
Yokohama, Japan, München, Deutschland und Allendale, New Jersey, USA. 24. September 2024. Minaris Regenerative Medicine (Minaris), ein führendes Auftragsentwicklungs- und Herstellungsunternehmen (CDMO) für Zelltherapien, freut sich bekanntzugeben, dass seine Mutterfirma, Resonac Corporation („Resonac“), eine endgültige Vereinbarung abgeschlossen hat über den Verkauf von Minaris an einen Fond, der ...
Taipei, Taiwan, and Yokohama, Japan - August 21st, 2024 - Celltech Innovation Venture Studio Co., Ltd. (“CellTech Accelerator”), the first cell and gene therapy accelerator in Asia, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnership to accelerate the ...
Taipei, Taiwan, and Yokohama, Japan - August 21st, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and Cell tech Innovation Venture Studio Co., Ltd. have entered into a business alliance. Details in Japanese for local news in Japan. Celltech Innovation Venture Studio Co., Ltd.（本社：台北、Founder & Chairman Johnny Yu、以下CellTech Accelerator）とMinaris Regenerative ...
NASHVILLE, Tenn., USA, and Yokohama, Japan - June 20th, 2024 - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”), a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnership to provide fully integrated logistics ...
Yokohama, Japan - June 20th, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and Cryoport, Inc. have entered into a business alliance. Details in Japanese for local news in Japan. Cryoport, Inc.（本社：テネシー州、CEO Jerrell W. Shelton、以下 Cryoport）とMinaris Regenerative Medicine株式会社（本社：神奈川県横浜市、代表取締役社長 坂東 博人、以下 Minaris）は、再生医療等製品の輸送に関する業務提携契約を締結しました。 ...
Lüneburg and Ottobrunn, Germany, June 13, 2024 – Minaris Regenerative Medicine GmbH (Minaris), a leading contract development and manufacturing organization for cell and gene therapies, has implemented a digital Manufacturing Execution System (MES), the newest version of Werum PAS-X MES by Körber, at its German site in Ottobrunn near Munich. By doing so, Minaris is converting its production ...